Storia in 3 fonti

Roche ends Huntington's gene-silencing programs

ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout

Raccontata da

statnews.com

biopharmadive.com

endpoints.news

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mese fa

Roche ends Huntington's gene-silencing programs

ARPA-H launches bespoke gene therapy push, Lilly and Novo to promote Bridge program, and more biotech news from The Readout

originale

biopharmadive.com1 mese fa

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.

Leggi questa versione → originale

Timeline cronologica

giovedì 9 luglio 2026·statnews.com
Prime wins Beam arbitration, clearing path to clinic
AstraZeneca, Ionis report major trial failure, White House pushes for American drug manufacturing, and more biotech news from The Readout
venerdì 10 luglio 2026·biopharmadive.com
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were…

Roche ends Huntington's gene-silencing programs

Confronto fonti

Roche ends Huntington's gene-silencing programs

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

Timeline cronologica

Prime wins Beam arbitration, clearing path to clinic

ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership

Deals, deals, deals; Biohaven takes on Eli Lilly; and more

Roche ends Huntington's gene-silencing programs

Deals, deals, deals; Biohaven takes on Eli Lilly; and more